Skip to main content
SpringerLink
Log in

Soluble Type II Transforming Growth Factor-β Receptor Inhibits Tumorigenesis by Augmenting Host Antitumor Immunity

  • Chapter
Transforming Growth Factor-β in Cancer Therapy, Volume II

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 1538 Accesses

Abstract

Transforming growth factor-β (TGF-β) is a potent inhibitor of immune cells including T-lymphocytes, natural killer (NK) cells, and antigen presenting cells (APCs). Because large amounts of TGF-β are often produced by tumors, it has been hypothesized that blockade of TGF-β would prevent the loss of antitumor immune activity and exert effective antitumor efficacy. Thus, a number of experimental studies have been performed in tumor models blocking TGF-β production, TGF-β receptor binding, or TGF-β signaling to augment host antitumor immune responses. In this chapter, we review studies employing blockade of TGF-β using a soluble type II transforming growth factor-β receptor (sTGF-βR) and discuss future ways in which TGF-β inhibition might enhance cancer immuno-therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701–705.

    Article  CAS  PubMed  Google Scholar 

  2. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117–129.

    Article  CAS  PubMed  Google Scholar 

  3. Akhurst RJ. TGF-β antagonists: why suppress a tumor suppressor? J Clin Investig 2002;109:1533–1536.

    CAS  PubMed  Google Scholar 

  4. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93–102.

    Article  CAS  PubMed  Google Scholar 

  5. Ranges GE, Figari IS, Espevik T, Palladino MA. Jr. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor. J Exp Med 1987;166:991–998.

    Article  CAS  PubMed  Google Scholar 

  6. Tada T, Ohzeki S, Utsumi K, et al. transforming growth factor-β-induced inhibition of T cell function: Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991;146:1077–1082.

    CAS  PubMed  Google Scholar 

  7. de Visser KE, Kast WM. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 1999;13:1188–1199.

    Article  PubMed  Google Scholar 

  8. Gorelik L, Flavell RA. transforming growth factor-β in T-cell biology. Nat Rev Immunol 2002;2:46–53.

    Article  CAS  PubMed  Google Scholar 

  9. Dumont N, Arteaga CL. transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2000;2:125–132.

    Article  CAS  PubMed  Google Scholar 

  10. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118–1122.

    Article  CAS  PubMed  Google Scholar 

  11. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993;92:2569–2576.

    Article  CAS  PubMed  Google Scholar 

  12. Suzuki E, Kapoor V, Cheung HK, et al. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004;10:5907–5918.

    Article  CAS  PubMed  Google Scholar 

  13. Odaka M, Sterman DH, Wiewrodt R, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201–6212.

    CAS  PubMed  Google Scholar 

  14. DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005;4:342–346.

    Article  CAS  PubMed  Google Scholar 

  15. Fitzpatrick DR, Bielefeldt-Ohman H, Himbeck RP, et al. transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994;11:29–44.

    Article  CAS  PubMed  Google Scholar 

  16. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992;52:881–886.

    Article  CAS  PubMed  Google Scholar 

  17. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037–1050.

    Article  CAS  PubMed  Google Scholar 

  18. Sad S, Mosmann TR. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol 1994;153:3514–3522.

    CAS  PubMed  Google Scholar 

  19. Swain SL, Huston G, Tonkonogy S, Weinberg A. transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol 1991;147:2991–3000.

    CAS  PubMed  Google Scholar 

  20. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann NY Acad Sci 1993;685:713–739.

    Article  CAS  PubMed  Google Scholar 

  21. Vodovotz Y, Bogdan C. Control of nitric oxide synthase expression by transforming growth factor-beta: implications for homeostasis. Prog Growth Factor Res 1994;5:341–351.

    Article  CAS  PubMed  Google Scholar 

  22. Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997;15:144–153.

    Article  CAS  PubMed  Google Scholar 

  23. Geissmann F, Revy P, Regnault A, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567–4575.

    CAS  PubMed  Google Scholar 

  24. Zheng H, Wang J, Koteliansky VE, Gotwals PJ, Hauer-Jensen M. Recombinant soluble transforming growth factor β type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 2000;119:1286–1296.

    Article  CAS  PubMed  Google Scholar 

  25. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12,719–12,724.

    Article  CAS  PubMed  Google Scholar 

  26. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999;84:1212–1222.

    CAS  PubMed  Google Scholar 

  27. Zhao W, Kobayashi M, Ding W, et al. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunol Immunother 2002;51:381–388.

    Article  CAS  PubMed  Google Scholar 

  28. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607–1615.

    CAS  PubMed  Google Scholar 

  29. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551–1559.

    CAS  PubMed  Google Scholar 

  30. Bandyopadhyay A, Lopez-Casillas F, Malik SN, et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 2002;62:4690–4695.

    CAS  PubMed  Google Scholar 

  31. Kobie JJ, Wu RS, Kurt RA, et al. transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63:1860–1864.

    CAS  PubMed  Google Scholar 

  32. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 2003;170:3806–3811.

    CAS  PubMed  Google Scholar 

  33. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

    Article  CAS  PubMed  Google Scholar 

  34. Folprecht G, Kohne CH. Drug Insight: metastatic colorectal cancer-oral fluoropyrimidines and new perspectives in the adjuvant setting. Nat Clin Pract Oncol 2005;2:578–587.

    Article  CAS  PubMed  Google Scholar 

  35. Dumont N, Arteaga CL. Targeting the TGF β signaling network in human neoplasia. Cancer Cell 2003; 3:531–536.

    Article  CAS  PubMed  Google Scholar 

  36. Laping NJ, Grygielko E, Mathur A, et al. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002;62:58–64.

    Article  CAS  PubMed  Google Scholar 

  37. Sawyer JS, Anderson BD, Beight DW, et al. Synthesis and activity of new aryl-and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 2003;46:3953–3956.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, Tokyo Metropolitan Komagome Hospital, Honkomagome, Bunkyo-ku, Tokyo, Japan

    Eiji Suzuki MD

  2. Laboratory of Thoracic Oncology, The University of Pennsylvania, Philadelphia, PA, USA

    Steven M. Albelda MD

Authors
  1. Eiji Suzuki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven M. Albelda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Training Branch, Office of Centers, Training and Resources, National Cancer Institute, Bethesda, MD

    Sonia B. Jakowlew PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Suzuki, E., Albelda, S.M. (2008). Soluble Type II Transforming Growth Factor-β Receptor Inhibits Tumorigenesis by Augmenting Host Antitumor Immunity. In: Jakowlew, S.B. (eds) Transforming Growth Factor-β in Cancer Therapy, Volume II. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-293-9_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-293-9_42

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-715-0

  • Online ISBN: 978-1-59745-293-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation